Thursday, December 22, 2016 11:30:52 AM
Without addressing the specifics of the idea I would ask you to consider these things:
1. The single example provided by its proponent of the use of a "warrant dividend" in the past involved a company that has nothing in common with NNVC at all. But they DID issue a warrant dividend. It had no value to shareholders and it no longer trades. There was no issue of a short position that was to be resolved by the dividend in the example.
2. A poster who I believe to be the shareholder proponent of the idea has posted that:
"The warrant dividend has never before, to the best of my knowledge, been used to force a short cabal to cover."
I believe I could provide the technical reasons for my calling the idea "nonsense", but they are boring and complicated...at least I think they would be to someone who cares primarily about the science. Instead I appeal to your basic sensibilities and you can see where they take you.
1. The idea has no history of being of ANY value to any shareholder as evidenced by the example provided by its proponent who also states that it has never been implemented with the goal intended in NNVC's case.
2. One of the elements of the idea is that the warrant would be traded separately from the stock on the open market but that it couldn't be transferred for a period of time...I believe the proposed period was 3 years. I would greatly appreciate it if you don't ask me to explain that.
(I have asked the person that I believe to be the idea's proponent and not heard back.)
3. Given the universe of shared wisdom in the markets and the universal appeal of the pot of gold at the end of the rainbow, is it reasonable to think that a process that hasn't been shown to even exist with the goal expressed here, let alone achieved that goal, would crop up in the context of a NanoViricides shareholder meeting?
4. Two words..."short cabal".
Good luck.
‘There are none so blind as those who will not see. The most deluded people are those who choose to ignore what they already know.’
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM